MORGAN STANLEY PLC/CALL/ZOETIS/260/0.1/19.09.25 Stock

Warrant

DE000ME3Y0D4

Real-time Bid/Ask 03:00:03 2024-05-31 am EDT
0.58 EUR / 0.62 EUR +3.45% Intraday chart for MORGAN STANLEY PLC/CALL/ZOETIS/260/0.1/19.09.25
Current month-4.92%
1 month-4.92%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-05-30 0.58 -14.71%
24-05-29 0.68 +6.25%
24-05-28 0.64 0.00%
24-05-27 0.64 -4.48%
24-05-24 0.67 -2.90%

Delayed Quote Börse Stuttgart

Last update May 30, 2024 at 11:59 am EDT

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying ZOETIS INC.
Issuer Morgan Stanley
WKN ME3Y0D
ISINDE000ME3Y0D4
Date issued 2023-11-20
Strike 260 $
Maturity 2025-09-19 (477 Days)
Parity 10 : 1
Emission price 0.61
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 2.05
Lowest since issue 0.41
Spread 0.04
Spread %6.45%

Company Profile

Zoetis Inc. specializes in developing, manufacturing and marketing of animal health products. Net sales break down by activity as follows: - pets (64.4%): cats and dogs (94.9% of net sales) and horses (5.1%); - livestock (34.5%): cattle (51.6% of sales), swine (20.2%), poultry (17.1%), fish (7.6%) and other (3.5%); - other (1.1%). Net sales break down by family of products into parasiticides (23%), vaccines (21.3%), dermatological products (16.4%), anti-infectives (13.4%), medical food additives (4.5%), diagnostic products (4.4%) and other (17%). At the end of 2022, the group has 29 production sites worldwide. The United States accounts for 53.4% of net sales.
Sector
-
More about the company

Ratings for Zoetis Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: Zoetis Inc.

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
169.4 USD
Average target price
211.2 USD
Spread / Average Target
+24.65%
Consensus